Further studies have found GLO1 amplification at very high prevalence in breast cancers that do not express estrogen receptor, progesterone receptor and HER-2 genes, triple-negative breast cancer (TNBC) [105], advanced malignant melanoma [106], and neuroendocrine tumors where increased GLO1 copy number was associated with poor patient survival [107]. This evidence concerns the gene GLO1 and breast carcinoma.